Načítá se...
Best practice in the use of natalizumab in multiple sclerosis
Natalizumab is approved for the treatment of patients with relapsing–remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinica...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3582310/ https://ncbi.nlm.nih.gov/pubmed/23483450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285612470401 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|